Local Treatment of Non-small Cell Lung Cancer with a Spray-Dried Bevacizumab Formulation
Open Access
- 31 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in AAPS PharmSciTech
- Vol. 22 (7), 1-11
- https://doi.org/10.1208/s12249-021-02095-7
Abstract
Local delivery of biotherapeutics to the lung holds great promise for treatment of lung diseases, but development of physically stable, biologically active dry powder formulations of large molecules for inhalation has remained a challenge. Here, spray drying was used to manufacture a dry powder pulmonary formulation of bevacizumab, a monoclonal antibody approved to treat non-small cell lung cancer (NSCLC) by intravenous infusion. By reformulating bevacizumab for local delivery, reduced side effects, lower doses, and improved patient compliance are possible. The formulation had aerosol properties suitable for delivery to the deep lung, as well as good physical stability at ambient temperature for at least 6 months. Bevacizumab’s anti-VEGF bioactivity was not impacted by the manufacturing process. The formulation was efficacious in an in vivo rat model for NSCLC at a 10-fold decrease in dose relative to the intravenous control.Keywords
This publication has 42 references indexed in Scilit:
- The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromoleculesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2013
- Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancerAnnals of Oncology, 2013
- Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug deliveryInternational Journal of Pharmaceutics, 2011
- Combination Therapy with Vidaza and Entinostat Suppresses Tumor Growth and Reprograms the Epigenome in an Orthotopic Lung Cancer ModelCancer Research, 2011
- Formulation Development and In Vivo Evaluation of a New Dry Powder Formulation of Albuterol Sulphate in Beagle DogsPharmaceutical Research, 2010
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiLJournal of Clinical Oncology, 2009
- Contribution of Variable Domains to the Stability of Humanized IgG1 Monoclonal AntibodiesJournal of Pharmaceutical Sciences, 2008
- BevacizumabDrugs, 2008
- Pharmaceutical Particle Engineering via Spray DryingPharmaceutical Research, 2007
- Glass Transition and Crystallization of Amorphous Trehalose-sucrose MixturesInternational Journal of Food Properties, 2005